GSK Awarded Up To $200M For Bioterror Drug Program

Law360, New York (May 22, 2013, 1:23 PM EDT) -- The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority said Wednesday it has awarded GlaxoSmithKline PLC up to $200 million in a groundbreaking effort to help develop new drugs to fight antibiotic resistance and bioterrorism.

BARDA said the agreement, under which the drugs will be developed under a public-private partnership agreement between GSK and the U.S., is the first time HHS has taken a portfolio approach with a private-sector company instead of contracting to develop a single medical countermeasure — a...
To view the full article, register now.